👤 Nidhi Bala

The fibroblast growth factor receptor 1 (FGFR1) plays a crucial role in cancer development and progression, primarily through mechanisms involving carcinogenesis and angiogenesis. Aberrant FGFR1 signalling has been implicated in various cancers, including lung, breast, neck and urothelial carcinoma. Despite the recognized oncogenic potential of FGFR1, therapeutic strategies targeting its kinase domain remain inadequately explored. This underscores an urgent need for the development of novel FGFR1 inhibitors, particularly through de novo drug design approaches, to effectively counteract FGFR1-driven malignancies. This research aims to develop novel FGFR1 inhibitors through a multi-step approach involving fragment-based drug design, virtual screening, molecular dynamics simulation (MD) and density functional theory studies (DFT), with the goal of targeting FGFR1's kinase binding domain to inhibit tumor angiogenesis. Initially, known FGFR inhibitor molecules were retrieved and subjected to fragment-based drug designing and virtual screening. Through thorough analysis, molecules containing the pyrido[2,3-d]pyrimidine scaffold were identified as promising candidates. A pyrido[2,3-d]pyrimidine-based database containing 90,952 molecules was subsequently retrieved from PubChem and filtered using molecular docking-based virtual screening resulting 94 molecules having better binding affinity than derazantinib, reference drug. After pharmacokinetic profiling (ADME), and MM-GBSA (Molecular Mechanics-Generalized Born Surface Area) studies, out of 94 molecules only 11 compounds with favorable pharmacokinetic properties and superior MM-GBSA binding free energies were selected. Docking-based screening revealed that selected 11 compounds demonstrated better binding scores than the reference drug, derazantinib. Among them, HIT1, was selected for 150ns molecular dynamics simulation to assess its conformational stability. DFT calculations further confirmed its bio-feasibility by analyzing the HOMO-LUMO energy gap. Overall, the selected lead compounds exhibited enhanced binding affinity, superior conformational stability, favorable pharmacokinetic and pharmacodynamic profiles compared to derazantinib. Present findings suggest that the identified hit molecules hold strong potential for inhibiting FGFR1's kinase domain and disrupting FGFR-associated tumor angiogenesis. Show less

To characterise severe hypertriglyceridaemia (HTG) in Indian children, focusing on clinical and genetic profiles. A retrospective analysis from January 2017 to December 2023 included children up to 14 years old with triglyceride (TG) levels > 500 mg/dl, excluding children with known secondary causes. Among 18 children with severe HTG, 7 had secondary causes. Data from 11 patients (7 boys, median age at diagnosis 0.9 [0.45-2.4] years) revealed presenting features such as lipemic serum (63.3%), failure to thrive (36.3%), loss of subcutaneous fat (18.2%), and abdominal distension (18.2%). Genetic aetiology was identified in 10 cases, with familial chylomicronaemia syndrome (FCS) being the most prevalent (6 cases) caused by the lipoprotein lipase (LPL) and apolipoprotein A-V (APOA5) gene mutations. One each had mutations in the 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2), lamin A/C (LMNA), glucose-6-phosphatase catalytic subunit (G6PC), and glycerol kinase (GK) genes. FCS patients presented earlier and were resistant to treatment targets, requiring drug therapy. At the final follow-up (mean duration 1.75 ±1.0 years) of 9 patients, the median TG levels for the FCS and non-FCS groups were 1240 (610-1,685) and 412 (247.5-993) mg/dl, respectively. Only 2 patients (40%) with FCS had TG levels < 1000 mg/dl, while all but one (75%) non-FCS subjects had TG levels < 500 mg/dl at the last follow-up. One child developed acute pancreatitis during the said duration. Paediatric HTG is often detected incidentally. Genetic characterisation is crucial for prognosis because baseline TG levels are non-predictive. Drug therapy helps to reach treatment targets in most of the patients. Show less